


## PHARMACEUTICAL 2022



## Cyclerion Therapeutics Inc. Rank 270 of 466





## PHARMACEUTICAL 2022



## Cyclerion Therapeutics Inc. Rank 270 of 466

The relative strengths and weaknesses of Cyclerion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cyclerion Therapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 29% points. The greatest weakness of Cyclerion Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 68% points.

The company's Economic Capital Ratio, given in the ranking table, is 89%, being 11% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	55,457
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,085
Liabilities, Non-Current	0
Other Assets	3,809
Other Compr. Net Income	0
Other Expenses	881
Other Liabilities	0
Other Net Income	3,548
Other Revenues	3,942
Property and Equipment	65
Research and Development	37,636
Selling, General and Administrative Expense	20,620

Output Variable	Value in 1000 USD
Assets	59,331
Liabilities	11,085
Expenses	59,137
Revenues	3,942
Stockholders Equity	48,246
Net Income	-51,647
Comprehensive Net Income	-51,647
Economic Capital Ratio	89%

